Navigation Links
ISTA Pharmaceuticals Initiates Clinical Development of Bepotastine Besilate Nasal Spray for the Treatment of Symptoms Associated with Seasonal Allergic Rhinitis
Date:7/14/2010

IRVINE, Calif., July 14 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), today announced it has initiated a Phase 1/2 clinical study of bepotastine besilate nasal spray for the treatment of symptoms associated with seasonal allergic rhinitis, the inflammation of the nasal passages caused by allergies.  The randomized, placebo-controlled, parallel-group study will evaluate the safety and efficacy of three concentrations of bepotastine besilate, dosed twice daily, in an Environmental Exposure Chamber (EEC) model of allergic rhinitis caused by natural exposure to seasonal allergens.  The study also will assess the pharmacokinetics (PK) of the investigational nasal sprays.

Following initial screening, 96 patients will be randomized into the Phase 1/2 clinical study.  During the study, patients will be exposed to pollen in the EEC and will grade their individual symptoms at select time intervals prior to and following dosing with bepotastine besilate nasal spray or placebo.  Reported symptoms will include both nasal symptoms and ocular symptoms.  Safety will be evaluated based on several variables, including adverse events, electrocardiograms, and the mean grades for questions on a brief satisfaction and tolerability questionnaire completed at the end of the study.  In addition, PK data on the three dose concentrations of bepotastine besilate nasal spray will be assessed based on blood draws from a subset of patients.

"This milestone attests to the continuing momentum of our programs addressing the allergy market," stated Vicente Anido, Jr., Ph.D., President and Chief Executive Officer of ISTA.  "Last year, we received FDA approval for BEPREVE, our eye drop treatment for itching associated with allergic conjunctivitis.  We now are looking forward to potentially expanding our allergy franchise with a formulation that can treat nasal allergies."

ISTA expects to complete the Phase 1/2 clinical study of bepotastine besilate nasal spray and announce preliminary results from the study in the fall of 2010.

About Allergic Rhinitis

According to the American Academy of Allergy Asthma & Immunology (AAAAI), approximately 60 million Americans are affected by allergic rhinitis, an inflammation of the nasal passages caused by exposure to certain allergens, such as pollen from trees, grass and plants, animal dander, feathers, dust mites and molds. Allergic rhinitis is characterized by a number of symptoms, including sneezing, nasal congestion, nasal itching and runny nose.  The eyes, ears, sinuses, and throat also can be affected.  Current treatments for allergic rhinitis include antihistamines, mast cell stabilizers, anti-inflammatories, and steroids.  Based on data from IMS Health, approximately 43.3 million prescriptions were filled for nasal allergy treatments in 2009, resulting in sales of approximately $2.2 billion.

About bepotastine besilate

Bepotastine besilate is a non-sedating, highly selective antagonist of the histamine H1 receptor.  It has a stabilizing effect on mast cells, and it suppresses the migration of eosinophils into inflamed tissues.  The compound's primary mechanisms of action are believed to make it an effective treatment for nasal symptoms associated with allergic rhinitis.

Bepotastine besilate has been approved in Japan for systemic use in the treatment of allergic rhinitis since 2000 and urticaria/pruritus since 2002.  It is marketed in Japan by Mitsubishi Tanabe Pharma Corporation (formerly Tanabe Seiyaku Co., Ltd.) under the brand name TALION®.  TALION was co-developed by Tanabe Seiyaku and Ube Industries, Ltd., who discovered bepotastine besilate.  In 2001, Tanabe Seiyaku granted Senju Pharmaceutical Co., Ltd., exclusive worldwide rights, with the exception of certain Asian countries, to develop, manufacture and market bepotastine besilate for ophthalmic use.  In 2006, ISTA licensed the exclusive North American rights from Senju to an eye drop formulation of bepotastine besilate for the treatment of allergic conjunctivitis.  In 2007, ISTA licensed exclusive North American rights to nasal dosage forms of bepotastine besilate from Tanabe Seiyaku and obtained a future right to negotiate for a North American license to oral dosage forms of bepotastine besilate for allergy treatment.

ISTA's eye drop formulation of bepotastine besilate, BEPREVE® (bepotastine besilate ophthalmic solution) 1.5%, was approved by the U.S. Food and Drug Administration (FDA) in September 2009 for the treatment of ocular itching associated with allergic conjunctivitis.  ISTA's nasal spray formulation for allergic rhinitis currently is in clinical studies and has not yet been approved by the FDA.

About ISTA Pharmaceuticals

ISTA Pharmaceuticals, Inc. is the fourth largest and fastest growing branded prescription eye care business in the United States, with an expanding focus on allergy therapeutics. ISTA currently markets four products, including treatments for ocular inflammation and pain post-cataract surgery, glaucoma and ocular itching associated with allergic conjunctivitis. The Company's development pipeline contains additional candidates in various stages of development to treat dry eye, ocular inflammation and pain and nasal allergies. Headquartered in Irvine, California, the Company generated 2009 revenues of $111 million. For additional information about ISTA Pharmaceuticals, please visit the corporate website at www.istavision.com.

Forward-looking Statements

Any statements contained in this press release that refer to future events or other non-historical matters are forward-looking statements.  Without limiting the foregoing, but by way of example, statements contained in this press release related to the expected initiation and completion of the clinical studies for bepotastine besilate nasal spray and the announcement of results in the fall of 2010 are forward-looking statements.  Except as required by law, ISTA disclaims any intent or obligation to update any forward-looking statements.  These forward-looking statements are based on ISTA's expectations as of the date of this press release and are subject to risks and uncertainties that could cause actual results to differ materially.  Important factors that could cause actual results to differ from current expectations include, among others, delays and uncertainties related to the FDA or other regulatory agency approval or actions and such other risks and uncertainties as detailed from time to time in ISTA's public filings with the U.S. Securities and Exchange Commission, including but not limited to ISTA's Annual Report on Form 10-K for the year ended December 31, 2009 and its Quarterly Report on Form 10-Q for the quarter ended March 31, 2010.


'/>"/>
SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ferring Pharmaceuticals FIRMAGON® Named Official Sponsor of Ed Randalls Bat for the Cure
2. Endo Pharmaceuticals Announces Expiration of Subsequent Offering Period of Tender Offer for HealthTronics, Inc.
3. Alexza Pharmaceuticals Updates Staccato® Pipeline and Outlines Pipeline Development Strategy
4. Jiangbo Pharmaceuticals to Attend Global Hunter Securities China Conference
5. ICAP Ocean Tomo Offers for Sale Advanced Drug Formulation Technology From CyDex Pharmaceuticals Inc.
6. Oramed Pharmaceuticals and sanofi-aventis Enter Into an Agreement for the Insulin Supply of Orameds Oral Insulin Capsules
7. Lotus Pharmaceuticals to Present at Global Hunter Securities 2010 China Conference
8. FDA Approves Strativa Pharmaceuticals Zuplenz® (ondansetron) Oral Soluble Film
9. Lilly to Acquire Alnara Pharmaceuticals
10. Renhuang Pharmaceuticals Receives Approval to List on the NYSE Amex
11. Jiangbo Pharmaceuticals Announces the Appointment of New Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/14/2017)... HAMPTON, Va. , June 14, 2017  ivWatch ... safety and effectiveness of intravenous (IV) therapy, is pleased ... in the category of Nonsurgical Hospital Supplies and Equipment ... premier awards program for the medtech industry. The award ... at the Jacob K. Javits Center in ...
(Date:6/11/2017)... , June 10, 2017  Eli Lilly and Company ... from three Phase 3 studies of galcanezumab, an investigational ... including late-breaking data on several key secondary endpoints for ... results from these studies (EVOLVE-1, EVOLVE-2 and REGAIN) will ... annual scientific meeting in Boston . ...
(Date:6/8/2017)... 2017   Responding to Heath Ledger,s father,s ... of singer Chris Cornell in May, the mental ... a free online psychiatric drug side effects ... about psychotropic drug risks. The father of ... an accidental overdose, has called for tighter rules on prescription ...
Breaking Medicine Technology:
(Date:6/23/2017)... (PRWEB) , ... June 23, 2017 , ... ... assistance and financial planning services to communities in the greater Chicago metropolitan area, ... to offer assistance to underprivileged youth in Chicago. , Founded in 1897, Hephzibah ...
(Date:6/22/2017)... ... ... Branches, Inc. has been partnering with The Miami Foundation for over 9 ... focused on providing opportunity to low-income families and breaking the cycle of generational poverty. ... to support its , Climb to College & Career initiative which focuses on postsecondary ...
(Date:6/22/2017)... ... June 22, 2017 , ... Children’s ... American Heart Association (AHA) to launch a Rheumatic Heart Disease Center, with the ... diagnosis of rheumatic heart disease (RHD) in high-risk, financially disadvantaged countries and low-income ...
(Date:6/22/2017)... ... 22, 2017 , ... A June 12 article in The Star ... apparent lack of oral hygiene by an aged parent who had recently suffered a ... a number of steps, including scheduling a dentist visit. Northridge Dental Works, a Los ...
(Date:6/20/2017)... ... June 20, 2017 , ... ... announces recipients of its annual “UBBIE” Awards (pronounced you-bee) for 2017. The ... significant achievements toward their involvement with UBA, the clients they serve, and the ...
Breaking Medicine News(10 mins):